Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer - PubMed (original) (raw)
doi: 10.1371/journal.pone.0000268.
Susan J Ramus, Susanne Krüger Kjaer, Estrid Hogdall, Richard A Dicioccio, Alice S Whittemore, Valerie McGuire, Claus Hogdall, Ian J Jacobs, Douglas F Easton, Bruce A J Ponder, Alison M Dunning, Simon A Gayther, Paul D P Pharoah
Affiliations
- PMID: 17342202
- PMCID: PMC1800910
- DOI: 10.1371/journal.pone.0000268
Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer
Honglin Song et al. PLoS One. 2007.
Abstract
Background: BRIP1 interacts with BRCA1 and functions in regulating DNA double strand break repair pathways. Germline BRIP1 mutations are associated with breast cancer and Fanconi anemia. Thus, common variants in the BRIP1 are candidates for breast and ovarian cancer susceptibility.
Methods: We used a SNP tagging approach to evaluate the association between common variants (minor allele frequency>or=0.05) in BRIP1 and the risks of breast cancer and invasive ovarian cancer. 12 tagging SNPs (tSNPs) in the gene were identified and genotyped in up to 2,270 breast cancer cases and 2,280 controls from the UK and up to 1,513 invasive ovarian cancer cases and 2,515 controls from the UK, Denmark and USA. Genotype frequencies in cases and controls were compared using logistic regression.
Results: Two tSNPs showed a marginal significant association with ovarian cancer: Carriers of the minor allele of rs2191249 were at reduced risk compared with the common homozygotes (Odds Ratio (OR) = 0.90 (95% CI, 0.82-1.0), P-trend = 0.045) and the minor allele of rs4988344 was associated with increased risk (OR = 1.15 (95%CI, 1.02-1.30), P-trend = 0.02). When the analyses were restricted to serous ovarian cancers, these effects became slightly stronger. These results were not significant at the 5% level after adjusting for multiple testing. None of the tSNPs was associated with breast cancer.
Conclusions: It is unlikely that common variants in BRIP1 contribute significantly to breast cancer susceptibility. The possible association of rs2191249 and rs4988344 with ovarian cancer risks warrant confirmation in independent case-control studies.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
Figure 1. Linkage disequilibrium between the 92 common variants (MAF>0.05) in HapMap CEPH trios.
Each square represents the correlation (r2) between each pair of SNPs with darker shades representing stronger LD. Tag SNPs are indicated with those SNPs that failed assay design being shown in grey font.
Similar articles
- BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
Weber-Lassalle N, Hauke J, Ramser J, Richters L, Groß E, Blümcke B, Gehrig A, Kahlert AK, Müller CR, Hackmann K, Honisch E, Weber-Lassalle K, Niederacher D, Borde J, Thiele H, Ernst C, Altmüller J, Neidhardt G, Nürnberg P, Klaschik K, Schroeder C, Platzer K, Volk AE, Wang-Gohrke S, Just W, Auber B, Kubisch C, Schmidt G, Horvath J, Wappenschmidt B, Engel C, Arnold N, Dworniczak B, Rhiem K, Meindl A, Schmutzler RK, Hahnen E. Weber-Lassalle N, et al. Breast Cancer Res. 2018 Jan 24;20(1):7. doi: 10.1186/s13058-018-0935-9. Breast Cancer Res. 2018. PMID: 29368626 Free PMC article. - Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL, Smith AM, Dávila MR, Sigurdson AJ, Giusti RM, Pineda MA, Doody MM, Tucker MA, Greene MH, Zhang J, Struewing JP. Rutter JL, et al. Hum Mutat. 2003 Aug;22(2):121-8. doi: 10.1002/humu.10238. Hum Mutat. 2003. PMID: 12872252 - Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
Durocher F, Labrie Y, Soucy P, Sinilnikova O, Labuda D, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Ouellette G, Pichette R, Plante M, Tavtigian SV, Simard J. Durocher F, et al. BMC Cancer. 2006 Sep 29;6:230. doi: 10.1186/1471-2407-6-230. BMC Cancer. 2006. PMID: 17010193 Free PMC article. - BRIP1, a potential candidate gene in development of non-BRCA1/2 breast cancer.
Ouhtit A, Gupta I, Shaikh Z. Ouhtit A, et al. Front Biosci (Elite Ed). 2016 Jan 1;8(2):289-98. doi: 10.2741/E767. Front Biosci (Elite Ed). 2016. PMID: 26709662 Review. - BRIP-1 germline mutation and its role in colon cancer: presentation of two case reports and review of literature.
Ali M, Delozier CD, Chaudhary U. Ali M, et al. BMC Med Genet. 2019 May 7;20(1):75. doi: 10.1186/s12881-019-0812-0. BMC Med Genet. 2019. PMID: 31064327 Free PMC article. Review.
Cited by
- Male Breast Cancer With Dual BRCA2 and BRIP1 Deleterious Gene Mutations.
Badve SB, Kim E, Sibia US, Borrego OT, Vara S, Damron A, Riker AI. Badve SB, et al. Ochsner J. 2024 Summer;24(2):157-161. doi: 10.31486/toj.23.0119. Ochsner J. 2024. PMID: 38912178 Free PMC article. - Molecular Genetic Characteristics of FANCI, a Proposed New Ovarian Cancer Predisposing Gene.
Fierheller CT, Alenezi WM, Serruya C, Revil T, Amuzu S, Bedard K, Subramanian DN, Fewings E, Bruce JP, Prokopec S, Bouchard L, Provencher D, Foulkes WD, El Haffaf Z, Mes-Masson AM, Tischkowitz M, Campbell IG, Pugh TJ, Greenwood CMT, Ragoussis J, Tonin PN. Fierheller CT, et al. Genes (Basel). 2023 Jan 20;14(2):277. doi: 10.3390/genes14020277. Genes (Basel). 2023. PMID: 36833203 Free PMC article. - A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene.
Fierheller CT, Guitton-Sert L, Alenezi WM, Revil T, Oros KK, Gao Y, Bedard K, Arcand SL, Serruya C, Behl S, Meunier L, Fleury H, Fewings E, Subramanian DN, Nadaf J, Bruce JP, Bell R, Provencher D, Foulkes WD, El Haffaf Z, Mes-Masson AM, Majewski J, Pugh TJ, Tischkowitz M, James PA, Campbell IG, Greenwood CMT, Ragoussis J, Masson JY, Tonin PN. Fierheller CT, et al. Genome Med. 2021 Dec 3;13(1):186. doi: 10.1186/s13073-021-00998-5. Genome Med. 2021. PMID: 34861889 Free PMC article. - CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients.
Lu N, Liu J, Xu M, Liang J, Wang Y, Wu Z, Xing Y, Diao F. Lu N, et al. Int J Gen Med. 2021 Nov 4;14:7647-7657. doi: 10.2147/IJGM.S335592. eCollection 2021. Int J Gen Med. 2021. PMID: 34764678 Free PMC article. - The repair gene BACH1 - a potential oncogene.
Muhseena N K, Mathukkada S, Das SP, Laha S. Muhseena N K, et al. Oncol Rev. 2021 Jul 2;15(1):519. doi: 10.4081/oncol.2021.519. eCollection 2021 Feb 26. Oncol Rev. 2021. PMID: 34322202 Free PMC article.
References
- Lynch HT, Casey MJ, Lynch J, White TE, Godwin AK. Genetics and ovarian carcinoma. Semin.Oncol, 1998;25:265–280. - PubMed
- Rahman N, Stratton MR. The genetics of breast cancer susceptibility. Annu Rev Genet, 1998;32:95–121. - PubMed
- Pharoah PD, Ponder BA. The genetics of ovarian cancer. Best Pract.Res Clin Obstet Gynaecol., 2002;16:449–468. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA71766/CA/NCI NIH HHS/United States
- P30 CA016056/CA/NCI NIH HHS/United States
- CA16056/CA/NCI NIH HHS/United States
- R01 CA61107/CA/NCI NIH HHS/United States
- Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous